• MLN8237 (Alisertib) Assay Workflows

  2026-10-01

  Build reproducible Aurora A experiments with MLN8237 (Alisertib), from nanomolar kinase interrogation to apoptosis and mitotic-phenotype profiling. This workflow also shows how the reference study can help distinguish Aurora-linked aneugenic effects from tubulin-driven mechanisms.

• CDK9 inhibitor (A3294): Practical Lab Guide

  2026-10-01

  CDK9 inhibitor (A3294) is a selective serine/threonine kinase inhibitor for probing CDK9-dependent transcription elongation and P-TEFb-related activity. It is suited to biochemical, cell viability, and MT4 HIV-1 propagation inhibition workflows, but it should not be treated as a broad CDK inhibitor or as evidence of clinical efficacy.

• Torin2 Workflows for mTOR-Driven Cancer Research

  2026-09-30

  Torin2 combines nanomolar mTOR inhibition with a practical workflow for pathway validation, viability profiling, and apoptosis assay design. This guide shows how to use it in medullary thyroid carcinoma models while separating mTOR-dependent effects from transcription-linked cell death signals highlighted by a recent preprint.

• Taltirelin, TRHR, and TH in Striatal Neurons

  2026-09-30

  Zhu et al. identify a TRHR–MAPK–RARα–DRD2 signaling axis through which Taltirelin induces tyrosine hydroxylase expression in striatal medium spiny neurons. The study provides a mechanistic explanation for Taltirelin-associated dopaminergic effects in Parkinson’s disease models while emphasizing that TH-positive striatal cells are not necessarily conventional midbrain dopaminergic neurons.

• RNA Pol II Inhibition and the PDAR Apoptotic Response

  2026-09-29

  Harper et al. show that RNA polymerase II inhibition kills cells through an active apoptotic program triggered by loss of hypophosphorylated RNA Pol IIA, rather than through passive depletion of transcripts and proteins. The study defines the Pol II degradation-dependent apoptotic response and provides a framework for interpreting transcription-targeting drugs and related cell-death experiments.

• Neomycin Sulfate as a Structure-First Probe

  2026-09-29

  Neomycin sulfate is more than an aminoglycoside antibiotic: it is a versatile probe for testing how RNA, DNA, and ion-channel structure controls biological function. This guide combines mechanistic interpretation with assay-design lessons from microbiome and immune research.

• X-press Tag Peptide for PTM Assay Design

  2026-09-28

  Discover how the X-press Tag Peptide can organize recombinant purification and detection workflows for studying RHEB neddylation and mTORC1 signaling. This article connects tag architecture with assay controls, sample integrity, and the limitations of translating mechanistic cancer biology into protein biochemistry.

• Torin2: A Selective mTOR Inhibitor for Cancer Research

  2026-09-28

  Torin2 is an mTOR inhibitor used to investigate mTOR signaling and cancer-cell responses. Product information reports an EC50 of 0.25 nM, while a cited dissertation cautions that relative viability and cell killing are distinct response measures.

• MHY1485: A Strategic Probe of mTOR–Autophagy

  2026-09-27

  MHY1485 offers translational researchers a way to interrogate mTOR signaling alongside autophagic flux. This article connects mechanistic evidence in uveal melanoma with practical assay design, model selection, and responsible interpretation across oncology and ovarian follicle research.

• Cy5 TSA Kit for Spatial Astrocyte Biology

  2026-09-26

  The Cy5 TSA Fluorescence System Kit can help translate astrocyte atlas findings into sensitive, spatially resolved tissue assays. This article explains how to plan that validation while accounting for developmental, regional, and species differences—and for the limits of enzyme-mediated signal amplification.

• Quizartinib (AC220): Reading FLT3 Assay Endpoints

  2026-09-25

  Quizartinib (AC220) is a potent FLT3 inhibitor, but a useful AML experiment depends on distinguishing target inhibition from downstream cell effects. This article presents an endpoint-first framework for interpreting FLT3 assays and draws a carefully bounded methods insight from research on norovirus protein secretion.

• Protease Inhibitor Cocktail for Plant Extracts

  2026-09-25

  Learn when protein degradation inhibition can improve plant-lysate readouts—and why it should be applied after, not during, live-cell viability assays. This scenario-based guide explains practical use and limitations of Protease Inhibitor Cocktail (EDTA-Free, 100X in DMSO), SKU K1011.

• MHY1485: mTOR Activator Workflows for Autophagy

  2026-09-24

  Use MHY1485 to probe how mTOR activation relates to autophagy, with a workflow that distinguishes pathway engagement from blocked autophagosome clearance. Practical guidance covers stock handling, dose-and-time pilots, uveal melanoma mechanism studies, and a separate ovarian follicle research application.

• Flumequine: Choosing the Right Drug-Response Readout

  2026-09-24

  Flumequine is a DNA topoisomerase II inhibitor for studying how enzyme perturbation affects cell growth and survival. This guide connects its mechanism to a key assay-design principle: proliferation arrest and cell killing are distinct outcomes and should be measured accordingly.

• Rotenone, Redox Signaling, and Assay Interpretation

  2026-09-23

  Rotenone is a mitochondrial Complex I inhibitor used to study bioenergetic stress, apoptosis, and neurodegeneration. This guide connects rotenone experiment design with new DPP9–KEAP1 findings while distinguishing established evidence from testable hypotheses.

8725 records 1/582 page Next 12345 下5页 Last page